BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia
Status:
Active, not recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out what effects, good and/or bad, treatment with
vemurafenib (also known as Zelboraf™) has on the patient and on leukemia. Specifically, the
researchers want to know how well vemurafenib eliminates leukemia from the blood.
Phase:
Phase 2
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborators:
Dana-Farber Cancer Institute National Cancer Institute (NCI) Northwell Health Northwestern University Ohio State University Scripps Clinic